Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGAV | P06756 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL753967 | 0.82 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAL3MBTL1ALDH1A1OPRM1 | |
| SCHEMBL890184 | 0.82 | POLB (0.46) | SMN1; SMN2LMNAL3MBTL1ALDH1A1OPRM1 | |
| SCHEMBL6641302 | 0.82 | MAPK1 (0.46) | SMN1; SMN2LMNAL3MBTL1ALDH1A1OPRM1 | |
| SCHEMBL14853051 | 0.81 | SMN1; SMN2 (0.43) | SMN1; SMN2LMNAL3MBTL1ALDH1A1OPRM1 | |
| SCHEMBL5404433 | 0.81 | TRPM8 (0.50) | SMN1; SMN2LMNAL3MBTL1ALDH1A1OPRM1 | |
| SCHEMBL8917155 | 0.80 | SMN1; SMN2 (0.38) | SMN1; SMN2LMNAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL12980850 | 0.80 | ALDH1A1 (0.46) | LMNAALDH1A1OPRM1OPRD1KMT2A | |
| SCHEMBL8921081 | 0.80 | ALDH1A1 (0.46) | LMNAALDH1A1OPRM1OPRD1KMT2A | |
| Hydrochloric Acid SCHEMBL2673895 | 0.79 | TRPM8 (0.49) | SMN1; SMN2LMNAL3MBTL1ALDH1A1OPRM1 | |
| SCHEMBL888851 | 0.79 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAL3MBTL1ALDH1A1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013052369-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | WO | disclosed |
| US-8188132-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-06-16 | — | — | US | disclosed |
| WO-2011031934-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2010148006-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| WO-2010099527-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | SMN1; SMN2 4162/4885LMNA 2800/4885L3MBTL1 2575/4885 |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | SMN1; SMN2 3741/4885LMNA 3064/4885L3MBTL1 1834/4885 |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | SMN1; SMN2 4162/4885LMNA 2800/4885L3MBTL1 2575/4885 |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | SMN1; SMN2 3515/4885LMNA 2724/4885L3MBTL1 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.